GEMMA Biotherapeutics – a new therapeutics company founded by gene therapy pioneer Dr. Jim Wilson – announced the completion of a $34 million seed funding round to accelerate its groundbreaking gene therapy initiatives.
The $34 million seed funding round was co-led by Double Point Ventures, Bioluminescence Ventures, and Earlybird Venture Capital, with additional backing from Savanne Life Sciences. This funding will fuel GEMMABio’s operational expansion and innovative gene therapy programs.
GEMMABio is at the forefront of advancing gene therapy research, focusing on accelerating the development and delivery of life-changing therapies to patients worldwide.
Since launching on October 1, 2024, GEMMABio has had several active programs, including a recently announced collaboration with Fiocruz, the main supplier of immunobiologics, biopharmaceuticals, and diagnostics to the Brazilian Ministry of Health.
As GEMMABio continues to build momentum, the company is looking to seek strategic partners to collaborate on its mission to bring innovative therapies to market.
KEY QUOTES:
“We are delighted by the enthusiastic support from our engaged and high-quality partners, who share our vision for the future of gene therapy. Their involvement comes at a pivotal moment in the industry, and together, we are committed to expanding and speeding access to affordable gene therapies for the patients who need them most.”
– Dr. Jim Wilson, President and CEO of GEMMABio
“We are excited to be part of GEMMABio’s journey from the outset, as the company is positioned for success with its technologies, continued innovation and unique partnerships. We are confident that GEMMABio’s patient-centered approach will not only deliver life-saving gene therapies to those who need them most but also drive meaningful value for shareholders.”
– Campbell Murray, Senior Partner at Bioluminescence Ventures
“GEMMABio’s innovative technology platform and ambitious mission to transform patient care make it a compelling partner. As the company accelerates the development and delivery of life-changing therapies, we are proud to support its journey to bring transformative solutions to patients worldwide.”
– Florent Gros, Partner at Earlybird Venture Capital
Leave a Reply